BioLamina was founded in 2009 in Sundyberg, Sweden and has engineered recombinant human laminin proteins that are revolutionising the development and manufacturing of regenerative cell therapeutics and disease models from both stem cells and primary cells. 

“Lauxera is impressed by the company’s development and supports BioLamina's plan to continue to expand its global footprint, widen its product offering, and scale its production capacity at multiple quality levels to meet the strong demand from both innovative biopharma players and from life science tools and services”.

BDO's Life Sciences CDD team is proud to have supported this investment and consolidate its position as strategic adviser within the stem cells and regenerative medicine field. Indeed, scale-up of cell products, new means of cell culture conditions such as 3D, or new cell models is the most relevant in today's regenerative medicine field and attracts high interests from private equity clients.